000283082 001__ 283082
000283082 005__ 20251231103633.0
000283082 0247_ $$2doi$$a10.1002/alz70860_100898
000283082 0247_ $$2ISSN$$a1552-5260
000283082 0247_ $$2ISSN$$a1552-5279
000283082 037__ $$aDZNE-2025-01489
000283082 082__ $$a610
000283082 1001_ $$0P:(DE-2719)9001238$$aPlaten, Moritz$$b0$$eFirst author$$udzne
000283082 1112_ $$aAlzheimer’s Association International Conference$$cToronto$$d2025-07-27 - 2025-07-31$$gAAIC 25$$wCanada
000283082 245__ $$aDifferentiation between early and severe stages of dementia using diagnosis, prescription and utilization patterns
000283082 260__ $$c2025
000283082 3367_ $$0PUB:(DE-HGF)1$$2PUB:(DE-HGF)$$aAbstract$$babstract$$mabstract$$s1767100136_6285
000283082 3367_ $$033$$2EndNote$$aConference Paper
000283082 3367_ $$2BibTeX$$aINPROCEEDINGS
000283082 3367_ $$2DRIVER$$aconferenceObject
000283082 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$mjournal
000283082 3367_ $$2DataCite$$aOutput Types/Conference Abstract
000283082 3367_ $$2ORCID$$aOTHER
000283082 520__ $$aBackground:Routinely collected claims data often lack clinical parameters like dementia severity, which are essential for treatments targeting early disease stages. Diagnoses, prescriptions, and healthcare service utilization patterns are commonly used to infer dementia severity, but evidence validating these patterns is limited.Objective:To identify and validate predictors (diagnoses, prescriptions, and utilization patterns) for differentiating early and more severe dementia stages.Methods:This cross-sectional analysis used baseline data from 737 dementia patients. Comprehensive assessments captured clinical data and healthcare utilization. Diagnoses and prescribed medications were extracted from general practitioner files. Dementia severity was categorized by the Mini-Mental State Examination (MMSE): early (≥27), mild (20–26), and moderate/severe (0–19). Ordinal logistic regression analyzed associations between predictors and severity, with average marginal effects (AME) quantifying their impact. Specificity and negative predictive values (NPV) were calculated to exclude milder stages.Results:The sample (56% female, mean age 80) was classified as early (18%), mild (43%), or moderate/severe (39%). Predictors of moderate/severe dementia included differential dementia diagnoses (OR 1.78), antipsychotics (OR 3.22), antidementia drugs (OR 2.12), and having a care level. Conversely, the number of medications (OR 0.91) and therapy use (occupational, speech, or physical; OR 0.68) were associated with milder stages. Antipsychotics reduced early-stage likelihood by 14% and increased moderate/severe likelihood by 21%. Antidementia drugs reduced early-stage likelihood by 9% and increased moderate/severe likelihood by 13%. Care level reduced early-stage probability by 2–16%, while moderate/severe probability increased by 3–34%. Antidementia and antipsychotic prescriptions showed a specificity of 95% and an NPV of 81%, reliably excluding early dementia. For mild dementia, specificity was 94%, but NPV dropped to 52%. Differential diagnoses and care levels had a specificity of 86% and NPV of 81%, effectively distinguishing early dementia.Conclusion:Prescription and diagnostic patterns reliably distinguish early from severe dementia, validating their use for inferring dementia stages from claims data. Further research should refine these predictors to support guideline-based, early-stage dementia therapies.
000283082 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x0
000283082 588__ $$aDataset connected to CrossRef, Journals: pub.dzne.de
000283082 7001_ $$0P:(DE-2719)9002138$$aBuchholz, Maresa$$b1$$udzne
000283082 7001_ $$0P:(DE-2719)9001134$$aRaedke, Anika$$b2$$udzne
000283082 7001_ $$0P:(DE-2719)9001251$$aScharf, Annelie$$b3$$udzne
000283082 7001_ $$0P:(DE-2719)9003305$$aGlaeser, Eva$$b4$$udzne
000283082 7001_ $$0P:(DE-2719)9003158$$aIskandar, Audrey$$b5$$udzne
000283082 7001_ $$0P:(DE-2719)2000040$$aHoffmann, Wolfgang$$b6$$udzne
000283082 7001_ $$0P:(DE-2719)2810763$$aMichalowsky, Bernhard$$b7$$eLast author$$udzne
000283082 773__ $$0PERI:(DE-600)2201940-6$$a10.1002/alz70860_100898$$gVol. 21, no. S6, p. e100898$$nS6$$pe100898$$tAlzheimer's and dementia$$v21$$x1552-5260$$y2025
000283082 8564_ $$uhttps://pub.dzne.de/record/283082/files/DZNE-2025-1489.pdf$$yOpenAccess
000283082 8564_ $$uhttps://pub.dzne.de/record/283082/files/DZNE-2025-1489.pdf?subformat=pdfa$$xpdfa$$yOpenAccess
000283082 909CO $$ooai:pub.dzne.de:283082$$popenaire$$popen_access$$pVDB$$pdriver$$pdnbdelivery
000283082 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9001238$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b0$$kDZNE
000283082 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9002138$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b1$$kDZNE
000283082 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9001134$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b2$$kDZNE
000283082 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9001251$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b3$$kDZNE
000283082 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9003305$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b4$$kDZNE
000283082 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9003158$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b5$$kDZNE
000283082 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2000040$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b6$$kDZNE
000283082 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2810763$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b7$$kDZNE
000283082 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x0
000283082 9141_ $$y2025
000283082 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2025-01-06
000283082 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2025-01-06
000283082 915__ $$0LIC:(DE-HGF)CCBY4$$2HGFVOC$$aCreative Commons Attribution CC BY 4.0
000283082 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bALZHEIMERS DEMENT : 2022$$d2025-01-06
000283082 915__ $$0StatID:(DE-HGF)3001$$2StatID$$aDEAL Wiley$$d2025-01-06$$wger
000283082 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2025-01-06
000283082 915__ $$0StatID:(DE-HGF)9910$$2StatID$$aIF >= 10$$bALZHEIMERS DEMENT : 2022$$d2025-01-06
000283082 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2025-01-06
000283082 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000283082 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2025-01-06
000283082 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2025-01-06
000283082 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2025-01-06
000283082 9201_ $$0I:(DE-2719)5000067$$kAG Michalowsky$$lPatient-Reported Outcomes and Health Economics Research$$x0
000283082 9201_ $$0I:(DE-2719)1510600$$kAG Hoffmann$$lTranslational Health Care Research$$x1
000283082 980__ $$aabstract
000283082 980__ $$aVDB
000283082 980__ $$aUNRESTRICTED
000283082 980__ $$ajournal
000283082 980__ $$aI:(DE-2719)5000067
000283082 980__ $$aI:(DE-2719)1510600
000283082 9801_ $$aFullTexts